Bluebird Financial Statements From 2010 to 2025

BLUE Stock  USD 7.91  0.36  4.77%   
Bluebird Bio financial statements provide useful quarterly and yearly information to potential Bluebird bio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bluebird Bio financial statements helps investors assess Bluebird Bio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bluebird Bio's valuation are summarized below:
Gross Profit
-21.2 M
Market Capitalization
76.9 M
Enterprise Value Revenue
6.9871
Revenue
54.9 M
Earnings Share
(36.00)
There are over one hundred nineteen available fundamental signals for Bluebird bio, which can be analyzed over time and compared to other ratios. Investors should ensure to validate all of Bluebird Bio's prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of January 31, 2025, Market Cap is expected to decline to about 29.1 B. In addition to that, Enterprise Value is expected to decline to about 29 B

Bluebird Bio Total Revenue

40.76 Million

Check Bluebird Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bluebird Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 34.4 M, Interest Expense of 30.6 M or Selling General Administrative of 126.8 M, as well as many indicators such as Price To Sales Ratio of 112, Dividend Yield of 0.0 or PTB Ratio of 9.18. Bluebird financial statements analysis is a perfect complement when working with Bluebird Bio Valuation or Volatility modules.
  
Check out the analysis of Bluebird Bio Correlation against competitors.
For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

Bluebird Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total AssetsB712 M886.8 M
Slightly volatile
Other Current Liabilities55 M75.7 M47.2 M
Slightly volatile
Total Current Liabilities121.9 M230.1 M106.6 M
Slightly volatile
Other Liabilities101.6 K107 K22 M
Pretty Stable
Property Plant And Equipment Net182.7 M267 M156.8 M
Slightly volatile
Current Deferred Revenue1.3 M1.4 M9.8 M
Pretty Stable
Accounts Payable15.4 M21.3 M13.5 M
Slightly volatile
Cash283.9 M255 M247.3 M
Pretty Stable
Non Current Assets Total353.8 M388.1 M306.7 M
Slightly volatile
Other Assets33.2 M59.9 M31.7 M
Slightly volatile
Cash And Short Term Investments242.3 M255 M583.9 M
Pretty Stable
Common Stock Total Equity431.4 K817.6 K436.7 K
Slightly volatile
Common Stock Shares Outstanding64.4 M109.8 M56.7 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B712 M888.5 M
Slightly volatile
Non Current Liabilities Total167.4 M258.2 M150.9 M
Slightly volatile
Other Current Assets26.2 M27.6 M46.8 M
Pretty Stable
Other Stockholder Equity5.4 B5.1 B2.5 B
Slightly volatile
Total Liabilities289.2 M488.3 M257.6 M
Slightly volatile
Property Plant And Equipment Gross181.3 M355.2 M167.5 M
Slightly volatile
Total Current Assets307.7 M323.9 M557.4 M
Pretty Stable
Short Term Debt127.9 M121.8 M38.7 M
Slightly volatile
Common Stock2.3 M2.2 M721.4 K
Slightly volatile
Property Plant Equipment351.8 M335.1 M150 M
Slightly volatile
Net Tangible Assets203 M213.7 M619 M
Very volatile
Net Receivables10.1 M13 M7.6 M
Slightly volatile
Capital Surpluse2.6 B4.7 B2.4 B
Slightly volatile
Deferred Long Term Liabilities38 M28.2 M31.2 M
Slightly volatile
Non Current Liabilities Other100.5 K105.8 K33.2 M
Pretty Stable
Short and Long Term Debt Total202 M379.9 M166.7 M
Slightly volatile
Long Term Debt Total134.8 M176.3 M117.3 M
Slightly volatile
Short and Long Term Debt123.9 M179.2 M117.8 M
Slightly volatile
Capital Lease Obligations208.4 M379.9 M176.6 M
Slightly volatile
Net Invested Capital166.3 M175.1 M1.2 B
Slightly volatile
Net Working Capital69.7 M73.4 M844.4 M
Slightly volatile
Capital Stock2.3 M2.2 M879.9 K
Slightly volatile

Bluebird Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization34.4 M32.8 M11.4 M
Slightly volatile
Selling General Administrative126.8 M190.3 M113.8 M
Slightly volatile
Total Revenue40.8 M33.9 M35.3 M
Pretty Stable
Other Operating Expenses378.9 M314.8 M324.2 M
Slightly volatile
Research Development255.3 M192.8 M221.3 M
Slightly volatile
Cost Of Revenue35.5 M30.2 M41.8 M
Pretty Stable
Total Operating Expenses366 M240.2 M315 M
Slightly volatile
Interest Income7.6 M8.9 M6.4 M
Slightly volatile
Reconciled Depreciation19 M32.8 M16.7 M
Slightly volatile
Extraordinary Items84.8 M95.4 M104 M
Slightly volatile
Non Recurring20.6 M23.2 M25.3 M
Slightly volatile

Bluebird Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation21.2 M22.3 M50.5 M
Slightly volatile
Begin Period Cash Flow280.3 M182.2 M242.6 M
Slightly volatile
Depreciation34.4 M32.8 M13.2 M
Slightly volatile
Capital Expenditures9.9 M10.4 M20.7 M
Pretty Stable
End Period Cash Flow309.2 M315.8 M269.5 M
Slightly volatile
Sale Purchase Of Stock87.8 M92.4 M156.3 M
Very volatile
Issuance Of Capital Stock288.6 M223.4 M519.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1121183.9 K
Slightly volatile
Days Sales Outstanding138145224
Slightly volatile
Stock Based Compensation To Revenue0.560.594.2985
Pretty Stable
Capex To Depreciation0.350.372.432
Slightly volatile
EV To Sales1161223.9 K
Slightly volatile
Payables Turnover1.982.085.9535
Slightly volatile
Sales General And Administrative To Revenue6.413.674.8712
Pretty Stable
Research And Ddevelopement To Revenue4.865.1220.2845
Very volatile
Capex To Revenue0.260.281.4211
Pretty Stable
Cash Per Share2.212.3211.3502
Pretty Stable
Days Payables Outstanding1721811.1 K
Pretty Stable
Intangibles To Total Assets0.02780.02990.038
Slightly volatile
Current Ratio1.541.627.5836
Slightly volatile
Receivables Turnover2.482.619.6573
Very volatile
Graham Number7.57.8936.4375
Very volatile
Debt To Equity1.61.530.4715
Slightly volatile
Capex Per Share0.07050.07420.4251
Very volatile
Revenue Per Share0.230.240.6732
Very volatile
Interest Debt Per Share1.672.841.9824
Slightly volatile
Debt To Assets0.50.480.1887
Slightly volatile
Days Of Payables Outstanding1721811.1 K
Pretty Stable
Ebt Per Ebit1.081.00.988
Slightly volatile
Total Debt To Capitalization0.590.570.2198
Slightly volatile
Debt Equity Ratio1.61.530.4715
Slightly volatile
Quick Ratio1.411.497.915
Slightly volatile
Net Income Per E B T0.780.90.9191
Slightly volatile
Cash Ratio1.211.274.5768
Slightly volatile
Days Of Sales Outstanding138145224
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.850.931.0409
Pretty Stable
Fixed Asset Turnover0.120.130.5014
Slightly volatile
Debt Ratio0.50.480.1887
Slightly volatile
Price Sales Ratio1121183.9 K
Slightly volatile
Asset Turnover0.02820.04290.0349
Very volatile

Bluebird Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap29.1 B56.4 B51.5 B
Slightly volatile
Enterprise Value29 B56.3 B51.3 B
Slightly volatile

Bluebird Fundamental Market Drivers

Cash And Short Term Investments221.8 M

Bluebird Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Bluebird Bio Financial Statements

Bluebird Bio stakeholders use historical fundamental indicators, such as Bluebird Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bluebird Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bluebird Bio's assets and liabilities are reflected in the revenues and expenses on Bluebird Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bluebird bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.3 M
Total Revenue33.9 M40.8 M
Cost Of Revenue30.2 M35.5 M
Stock Based Compensation To Revenue 0.59  0.56 
Sales General And Administrative To Revenue 3.67  6.41 
Research And Ddevelopement To Revenue 5.12  4.86 
Capex To Revenue 0.28  0.26 
Revenue Per Share 0.24  0.23 
Ebit Per Revenue(9.52)(10.00)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:
Check out the analysis of Bluebird Bio Correlation against competitors.
For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(36.00)
Revenue Per Share
0.357
Quarterly Revenue Growth
1.337
Return On Assets
(0.36)
Return On Equity
(1.87)
The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.